Glucagonoma

Glucagonoma is a rare, functioning type of pancreatic neuroendocrine tumor (PNET; see this term) that hypersecretes glucagon, leading to a syndrome comprised of necrolytic migratory erythema, diabetes mellitus, anemia, weight loss, mucosal abnormalities, thromboembolism, gastrointestinal and neuropsychiatric symptoms.

Hypergastrinemia



Total: 3

                       


(per page)
PMID (PMCID)
11277423
 MALE Middle Aged
Immunohistochemical assessment of an asymptomatic glucagonoma in a patient with hypergastrinemia and marked antral angiodysplasia.
Weitgasser R, Sungler P, Hauser-Kronberger C, Dietze O, Sattlegger P, Hacker GW.
Appl Immunohistochem Mol Morphol. 2001;9(1):92-6.
Immunohistochemical assessment of an asymptomatic glucagonoma in a patient with hypergastrinemia and marked antral angiodysplasia.
11277423
 MALE Middle Aged
Immunohistochemical assessment of an asymptomatic glucagonoma in a patient with hypergastrinemia and marked antral angiodysplasia.
Weitgasser R, Sungler P, Hauser-Kronberger C, Dietze O, Sattlegger P, Hacker GW.
Appl Immunohistochem Mol Morphol. 2001;9(1):92-6.
We thus found antral angiodysplasia with hypergastrinemia leading to detection of a glucagonoma diagnosed by immunohistochemistry.
2852126
 FEMALE Adult
[Inhibitory effects of somatostatin analog (SMS 201-995) on pancreatic hormones in patients with malignant islet-cell carcinoma].
Fukushima H, Ueno S, Sakakida M, Takahashi T, Shirotani T, Araki E, Kishikawa H, Yamaguchi K, Nakamura N, Uzawa H, et al..
Nihon Naibunpi Gakkai Zasshi. 1988;64(8):666-76.
In Patient 1 with glucagonoma syndrome and hypergastrinemia, a prompt and remarkable decrease in plasma IRG and gastrin was observed after the injection of SMS 201-995 in association with a decrease in blood glucose, and then IRG and gastrin increased gradually.